Penserra Capital Management LLC Has $69,000 Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Posted by on Feb 28th, 2023

Penserra Capital Management LLC reduced its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) by 64.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,604 shares of the company’s stock after selling 41,151 shares during the period. Penserra Capital Management LLC’s holdings in Ginkgo Bioworks were worth $69,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth about $30,000. Atria Wealth Solutions Inc. acquired a new stake in Ginkgo Bioworks during the 2nd quarter worth about $30,000. Lake Street Financial LLC acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth about $31,000. Avantax Advisory Services Inc. acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth about $31,000. Finally, Cetera Investment Advisers acquired a new stake in Ginkgo Bioworks during the 2nd quarter worth about $33,000. 61.83% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Trading Down 0.7 %

NYSE DNA opened at $1.46 on Tuesday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $1.41 and a 52 week high of $4.91. The business has a 50 day moving average price of $1.75 and a 200-day moving average price of $2.30. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71.

Insider Activity

In related news, insider Jason R. Kelly sold 258,748 shares of the company’s stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $1.73, for a total transaction of $447,634.04. Following the completion of the sale, the insider now owns 14,947,040 shares in the company, valued at $25,858,379.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Jason R. Kelly sold 258,748 shares of the company’s stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $1.73, for a total transaction of $447,634.04. Following the completion of the sale, the insider now owns 14,947,040 shares in the company, valued at $25,858,379.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Reshma P. Shetty sold 100,429 shares of the company’s stock in a transaction on Thursday, December 1st. The stock was sold at an average price of $1.97, for a total value of $197,845.13. Following the sale, the insider now owns 20,018,754 shares of the company’s stock, valued at approximately $39,436,945.38. The disclosure for this sale can be found here. Insiders sold a total of 5,422,531 shares of company stock worth $9,441,984 over the last quarter. 17.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on DNA shares. Raymond James decreased their target price on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research report on Tuesday, November 22nd. Berenberg Bank initiated coverage on Ginkgo Bioworks in a report on Monday, November 28th. They set a “buy” rating and a $6.00 price objective for the company. Finally, BTIG Research decreased their price objective on Ginkgo Bioworks to $4.00 in a report on Thursday, November 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $5.76.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Articles

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.